Measurable Supratentorial White Matter Volume Changes in Patients with Diffuse Intrinsic Pontine Glioma Treated with an Anti-Vascular Endothelial Growth Factor Agent, Steroids, and Radiation

References

1. 1.↵
   2. Pope WB,
   3. Young JR,
   4. Ellingson BM

   . Advances in MRI assessment of gliomas and response to anti-VEGF therapy. Curr Neurol Neurosci Rep 2011;11:336–44 doi:10.1007/s11910-011-0179-x pmid:21234719

   CrossRefPubMed
2. 2.↵
   2. Broniscer A,
   3. Baker JN,
   4. Tagen M, et al

   . Phase I study of vandetanib during and after radiotherapy in children with diffuse intrinsic pontine glioma. J Clin Oncol 2010;28:4762–68 doi:10.1200/JCO.2010.30.3545 pmid:20921456

   Abstract/FREE Full Text
3. 3.↵
   2. Ji Q,
   3. Glass JO,
   4. Reddick WE

   . A novel, fast entropy-minimization algorithm for bias field correction in MR images. Magn Reson Imaging 2007;25:259–64 doi:10.1016/j.mri.2006.09.012 pmid:17275623

   CrossRefPubMedWeb of Science
4. 4.↵
   2. Glass JO,
   3. Reddick WE,
   4. Reeves C, et al

   . Improving the segmentation of therapy-induced leukoencephalopathy in children with acute lymphoblastic leukemia using a priori information and a gradient magnitude threshold. Magn Reson Med 2004;52:1336–41 doi:10.1002/mrm.20259 pmid:15562471

   CrossRefPubMed
5. 5.↵
   2. Reddick WE,
   3. Glass JO,
   4. Cook EN, et al

   . Automated segmentation and classification of multispectral magnetic resonance images of brain using artificial neural networks. IEEE Trans Med Imaging 1997;16:911–18 doi:10.1109/42.650887 pmid:9533591

   CrossRefPubMedWeb of Science
6. 6.↵
   2. Poussaint TY,
   3. Kocak M,
   4. Vajapeyam S, et al

   . MRI as a central component of clinical trials analysis in brainstem glioma: a report from the Pediatric Brain Tumor Consortium (PBTC). Neuro Oncol 2011;13:417–27 doi:10.1093/neuonc/noq200 pmid:21297126

   Abstract/FREE Full Text
7. 7.↵
   2. Gagner JP,
   3. Law M,
   4. Fischer I, et al

   . Angiogenesis in gliomas: imaging and experimental therapeutics. Brain Pathol 2005;15:342–63 pmid:16389946

   PubMedWeb of Science
8. 8.↵
   2. Rich JN,
   3. Sathornsumetee S,
   4. Keir ST, et al

   . ZD6474, a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor, inhibits tumor growth of multiple nervous system tumors. Clin Cancer Res 2005;11:8145–57 doi:10.1158/1078-0432.CCR-05-0319 pmid:16299247

   Abstract/FREE Full Text
9. 9.↵
   2. Gerstner ER,
   3. Duda DG,
   4. di Tomaso E, et al

   . VEGF inhibitors in the treatment of cerebral edema in patients with brain cancer. Nat Rev Clin Oncol 2009;6:229–36 doi:10.1038/nrclinonc.2009.14 pmid:19333229

   CrossRefPubMed
10. 10.↵
    2. Dietrich J,
    3. Rao K,
    4. Pastorino S, et al

    . Corticosteroids in brain cancer patients: benefits and pitfalls. Expert Rev Clin Pharmacol 2011;4:233–42 doi:10.1586/ecp.11.1 pmid:21666852

    CrossRefPubMed
11. 11.↵
    2. Martin P,
    3. Oliver S,
    4. Kennedy SJ, et al

    . Pharmacokinetics of vandetanib: three phase I studies in healthy subjects. Clin Ther 2012;34:221–37 doi:10.1016/j.clinthera.2011.11.011 pmid:22206795

    CrossRefPubMed
12. 12.↵
    2. Hoogervorst EL,
    3. Polman CH,
    4. Barkhof F

    . Cerebral volume changes in multiple sclerosis patients treated with high-dose intravenous methylprednisolone. Mult Scler 2002;8:415–19 doi:10.1191/1352458502ms838oa pmid:12356209

    CrossRefPubMedWeb of Science
13. 13.↵
    2. Rao AB,
    3. Richert N,
    4. Howard T, et al

    . Methylprednisolone effect on brain volume and enhancing lesions in MS before and during IFNbeta-1b. Neurology 2002;59:688–94 doi:10.1212/WNL.59.5.688 pmid:12221158

    Abstract/FREE Full Text
14. 14.↵
    2. Bendszus M,
    3. Weijers HG,
    4. Wiesbeck G, et al

    . Sequential MR imaging and proton MR spectroscopy in patients who underwent recent detoxification for chronic alcoholism: correlation with clinical and neuropsychological data. AJNR Am J Neuroradiol 2001;22:1926–32 pmid:11733327

    Abstract/FREE Full Text
15. 15.↵
    2. Bartsch AJ,
    3. Homola G,
    4. Biller A, et al

    . Manifestations of early brain recovery associated with abstinence from alcoholism. Brain 2007;130(pt 1):36–47 pmid:17178742

    Abstract/FREE Full Text
16. 16.↵
    2. Guerrini R,
    3. Belmonte A,
    4. Canapicchi R, et al

    . Reversible pseudoatrophy of the brain and mental deterioration associated with valproate treatment. Epilepsia 1998;39:27–32 doi:10.1111/j.1528-1157.1998.tb01270.x pmid:9578009

    CrossRefPubMedWeb of Science
17. 17.↵
    2. Panigrahy A,
    3. Nelson MD Jr.,
    4. Finlay JL, et al

    . Metabolism of diffuse intrinsic brainstem gliomas in children. Neuro Oncol 2008;10:32–44 doi:10.1215/15228517-2007-042 pmid:18003889

    Abstract/FREE Full Text
18. 18.↵
    2. Löbel U,
    3. Hwang S,
    4. Edwards A, et al

    . Discrepant longitudinal volumetric and metabolic evolution of diffuse intrinsic pontine gliomas during treatment: implications for current response assessment strategies. Neuroradiology 2016;58:1027–34 doi:10.1007/s00234-016-1724-8 pmid:27438806

    CrossRefPubMed
19. 19.↵
    2. Wen PY,
    3. Macdonald DR,
    4. Reardon DA, et al

    . Updated response assessment criteria for high-grade gliomas: Response Assessment in Neuro-Oncology working group. J Clin Oncol 2010;28:1963–72 doi:10.1200/JCO.2009.26.3541 pmid:20231676

    Abstract/FREE Full Text
20. 20.↵
    2. Warren KE,
    3. Poussaint TY,
    4. Vezina G, et al

    . Challenges with defining response to antitumor agents in pediatric neuro-oncology: a report from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group. Pediatr Blood Cancer 2013;60:1397–401 doi:10.1002/pbc.24562 pmid:23625747

    CrossRefPubMedWeb of Science
21. 21.↵
    2. Hipp SJ,
    3. Steffen-Smith E,
    4. Hammoud D, et al

    . Predicting outcome of children with diffuse intrinsic pontine gliomas using multiparametric imaging. Neuro Oncol 2011;13:904–09 doi:10.1093/neuonc/nor076 pmid:21757444

    Abstract/FREE Full Text
22. 22.↵
    2. Sedlacik J,
    3. Winchell A,
    4. Kocak M, et al

    . MR imaging assessment of tumor perfusion and 3D segmented volume at baseline, during treatment, and at tumor progression in children with newly diagnosed diffuse intrinsic pontine glioma. AJNR Am J Neuroradiol 2013;34:1450–55 doi:10.3174/ajnr.A3421 pmid:23436052

    Abstract/FREE Full Text
23. 23.↵
    2. Lober RM,
    3. Cho YJ,
    4. Tang Y, et al

    . Diffusion-weighted MRI derived apparent diffusion coefficient identifies prognostically distinct subgroups of pediatric diffuse intrinsic pontine glioma. J Neurooncol 2014;117:175–82 doi:10.1007/s11060-014-1375-8 pmid:24522717

    CrossRefPubMed
24. 24.
    2. Czock D,
    3. Keller F,
    4. Rasche FM, et al

    . Pharmcokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet 2005;44:61–98 doi:10.2165/00003088-200544010-00003 pmid:15634032

    CrossRefPubMedWeb of Science
25. 25.
    2. Yang L,
    3. Panetta JC,
    4. Cai X, et al

    . Asparaginase may influence dexamethasone pharmacokinetics in acute lymphoblastic leukemia. J Clin Oncol 2008;26:1932–39 doi:10.1200/JCO.2007.13.8404 pmid:18421047

    Abstract/FREE Full Text